Vertex Gears Up For Next Generation In CF Therapy
This article was originally published in Scrip
Vertex Pharmaceuticals Inc.'s newest cystic fibrosis drug Orkambi (lumacaftor/ivacaftor) has exceeded Wall Street projections for prescriptions and patient starts, the company reported during its third quarter earnings call Oct. 28.
You may also be interested in...
Moderna Therapeutics LLC extended its dealmaking streak and signaled a shift for its collaborative strategy by signing a partnership with Vertex Pharmaceuticals Inc. to develop a cystic fibrosis (CF) therapy based on the private biotechnology firm's messenger RNA (mRNA)-based drug development technology.
The firms’ partnership goes back to pre-merger Celgene, and BMS still has Dragonfly candidates in its pipeline. Ji Xing gets hypertension candidate from Phase Bio.
Mounjaro’s fourth quarter sales disappointed some analysts, but the launch remains off to a strong start. Donanemab now on track for full approval in Alzheimer’s, CEO Ricks pledges.